EN DE
Watch Cabaletta Bio, Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Cabaletta Bio, Inc (CABA) fair value: what the stock is really worth

As of Oct 30, 2026: fair value (intrinsic value) of Cabaletta Bio, Inc stock $0.43, price $1.51, that is 71.3% below the price, quality 30 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US12674W1099

CB Cabaletta Bio, Inc logo Thin data Oct 30, 2026

Cabaletta Bio, Inc

CABA · US
Very expensive, weak quality

Our calculation puts a fair price 71% below what the stock costs today.

Fair value $0.4335 · Strongly overvalued (−71.3%)
Quality 30/100
Weak Growth
Negative free cash flow
Trails peers (2/7)
Narrow moat 9/100
Thin data
⚠ Dilution
Watch Cabaletta Bio, Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$25.38 $0.6290 Fair Value $0.4335 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Oct 30, 2026.

How to read this chart

60‑month range $0.6290 – $25.38 · fair‑value band $0.2805 – $0.5355 · the $1.51 price screens above the $0.4335 fair value. As of Oct 30, 2026.

Follow Cabaletta Bio in your weekly email

Every Wednesday you see whether Cabaletta Bio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.

Show moreShow less

The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.

It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis.

It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018.

Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Stock analysis

Cabaletta Bio, Inc (CABA) currently trades at $1.51, while our model-based Fair Value estimate is $0.4335, 71.3% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $0.2805 (bear) to $0.5355 (bull), the price of $1.51 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Cabaletta Bio, Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$168M in FY2025.

Key figures

Market cap $256M Micro · EPS (TTM) $−1.51 · Return on equity −93.2% · Return on assets (EBIT) −56.9% · Free cash flow −$132M · Net cash $55.9M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 64% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −71%, CABA screens richer than that median.

Fair Value models

Bear $0.2805 Fair Value $0.4335 Bull $0.5355
Price $1.51 · Upside -71.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $0.3300 $0.5100 $0.6300 52
All 1 models by family
Asset-Based
NCAV (Graham) $0.3300 $0.5100 $0.6300 52

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 19
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 64
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 4
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CABA screens overvalued: fair value 71% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Cabaletta Bio, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 557 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −71.3% · Below median
Profitability
Return on assets −101.7% · Bottom 25%
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.28× · Pricier than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $927.89 $1,275 +37% vs CABA
WuXi Biologics (Cayman) Inc 2269 HK$44.48 HK$49.57 +11% vs CABA
Vertex Pharmaceuticals Incorporated VRTX $558.88 $614.77 +10% vs CABA
Samsung Biologics Co 207940 1,487,000 KRW 1,635,700 KRW +10% vs CABA
Genmab A/S GMAB kr 3,912 kr 4,303 +10% vs CABA
argenx SE ARGX $892.87 $908.40 +2% vs CABA
CSL Limited CSL A$201.16 A$178.62 −11% vs CABA
BeOne Medicines AG ONC $370.33 $254.12 −31% vs CABA
Celltrion, Inc 068270 191,600 KRW 74,945 KRW −61% vs CABA
Royalty Pharma plc RPRX $67.18 $19.01 −72% vs CABA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cabaletta Bio, Inc · Fair Value
$0.4335 −71%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Cabaletta Bio, Inc Fair Value". https://www.fairvalue-calculator.com/stock/CABA

Frequently asked questions

Is Cabaletta Bio, Inc (CABA) overvalued or undervalued?
As of Oct 30, 2026, our model estimates a fair value of $0.4335 versus a price of $1.51, about 71% lower (overvalued).
What is the fair value of CABA?
Our model-based fair value for Cabaletta Bio, Inc is $0.4335 (as of Oct 30, 2026), built from audited fundamentals. The current price: $1.51.
What is the quality score of CABA?
Cabaletta Bio, Inc has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cabaletta Bio, Inc (CABA)?
Our model-based price target is the fair value of $0.4335 (as of Oct 30, 2026) from 1 valuation models. Cautious scenario $0.2805, optimistic scenario $0.5355. It is a calculation from audited fundamentals, not an analyst target.
What is the Cabaletta Bio, Inc stock forecast for 2026?
Our models put fair value at $0.4335, about 71% lower versus a price of $1.51 (overvalued). Cautious scenario $0.2805, optimistic scenario $0.5355. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Cabaletta Bio, Inc (CABA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cabaletta Bio, Inc it is $0.4335 per share (as of Oct 30, 2026), against a price of $1.51. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Cabaletta Bio, Inc stock overvalued or undervalued in 2026?
As of Oct 30, 2026, CABA trades above its calculated fair value: price $1.51, fair value $0.4335, a gap of about −71% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CABA?
No. The price is what the market pays today ($1.51); the fair value is what the company's own numbers justify ($0.4335). For Cabaletta Bio, Inc the two are $1.08 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cabaletta Bio, Inc worth?
The market values Cabaletta Bio, Inc at about $256M (market capitalisation, as of Oct 30, 2026). Per share that is $1.51; our models calculate a fair value of $0.4335 per share.
What do the bullish and bearish scenarios say about CABA?
Our models span a range for Cabaletta Bio, Inc: cautious scenario $0.2805, base $0.4335, optimistic $0.5355 per share (as of Oct 30, 2026, price $1.51). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cabaletta Bio, Inc (CABA)?
Balance-sheet figures for Cabaletta Bio, Inc (as of Oct 30, 2026): return on equity −93.2%. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is CABA from its 52-week high?
Cabaletta Bio, Inc trades at $1.51, about 64% below its 52-week high of $4.15 and 12% above the low of $1.35 (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of $0.4335 is for.
Which stocks are comparable to Cabaletta Bio, Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cabaletta Bio, Inc stock attractive at the current price?
The data as of Oct 30, 2026: price $1.51, calculated fair value $0.4335 (−71%), Quality Score 30/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CABA calculated?
We run Cabaletta Bio, Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.4335, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Cabaletta Bio, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cabaletta Bio, Inc (CABA)?
The closing price on Oct 30, 2026 was $1.51. Our model-based fair value is $0.4335, about 71% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cabaletta Bio, Inc right now?
The price sits above even our optimistic bull case ($0.5355). The favourable scenario is already priced in. Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.2805 to $0.5355) leaves room in how you read the outcome.

Key figures of Cabaletta Bio, Inc

How large is the market capitalisation of Cabaletta Bio, Inc (CABA)?
The market capitalisation of Cabaletta Bio, Inc is $256M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Cabaletta Bio, Inc (CABA)?
Earnings per share at Cabaletta Bio, Inc are $−1.51. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Cabaletta Bio, Inc (CABA)?
The return on equity (ROE) of Cabaletta Bio, Inc is −93.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cabaletta Bio, Inc (CABA)?
On an EBIT basis the return on assets of Cabaletta Bio, Inc is −56.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Cabaletta Bio, Inc (CABA) generate?
The free cash flow of Cabaletta Bio, Inc is −$132M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Cabaletta Bio, Inc (CABA) hold?
Cabaletta Bio, Inc holds more cash than debt, $55.9M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Cabaletta Bio, Inc in the live analysis

One click puts Cabaletta Bio, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.